GlassScriptPhysician profile
Dylan T Timberlake
NPI 1730574328
$737.43
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.29 · 2022: $270 · 2023: $403 · 2024: $50.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $453.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $452.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $242.94 | 2022-2024 | Tezspire, Fasenra |
| Genzyme Corporation | $185.97 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $65.37 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.99 | 2022-2024 | Takhzyro |
| Glaxosmithkline, LLC. | $49.69 | 2023 | Nucala |
| Teva Pharmaceuticals USA, INC. | $29.15 | 2022 | |
| Csl Behring | $25.45 | 2022 | |
| Amgen INC. | $18.51 | 2022 | |
| Pfizer INC. | $14.95 | 2023 | |
| Kaleo, INC. | $14.44 | 2022 | |
| Biocryst US Sales Co., LLC | $14.29 | 2021 | |
| Genentech USA, INC. | $13.70 | 2023 | Xolair |
| Incyte Corporation | $12.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dylan Timberlake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.